Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
NCT ID: NCT00025818
Last Updated: 2011-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
290 participants
INTERVENTIONAL
2001-05-31
2003-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
NCT02420730
A Clinical Trial to Assess Subjects With Dry Eye Disease.
NCT04971031
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
NCT02435914
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02965846
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
NCT00001731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ophthalmic Emulsion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of moderate to severe dry eyes for at least 6 months and meet one or all of the following criteria:
* Diagnosis of autoimmune disorder
* Female 65 years of age or older
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Allergan, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eyecare of La Jolla
La Jolla, California, United States
UCLA
Los Angeles, California, United States
Opticare
Waterbury, Connecticut, United States
Brandon Eye Clinic
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
UIC Eye Center
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Hunkleler Eye Center
Overland Park, Kansas, United States
D'Ambrosio Eye Care
Leominster, Massachusetts, United States
Great Lakes Eye Institute
Saginaw, Michigan, United States
Cornea Consultants of Albany
Albany, New York, United States
Dr. Freedman's Office
Brooklyn, New York, United States
Dr. Wittpen's Office
Stony Brook, New York, United States
The Cole Eye Institute
Cleveland, Ohio, United States
Northwest Cornea
Portland, Oregon, United States
Corona Research
El Paso, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
192371-011-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.